新辅助化疗在宫颈癌治疗中的应用(1)
摘要：目的 评价新辅助化疗在宫颈癌治疗中的效果，为宫颈癌治疗工作的开展提供参考。方法 选择我院2016年8月～2018年3月收治的宫颈癌患者60例。以随机数字表法分为对照组和观察组，各30例。对照组接受常规手术治疗，观察组在术前给予新辅助化疗治疗。对比两组宫颈癌患者术中出血量、手术时间、治疗效果以及术后并发症情况、患者治疗效果满意度评分。结果观察组宫颈癌患者手术时间为(144.50±23.50)min，短于对照组的(224.50±28.50)min(P<0.05);术后并发症总发生率为16.67%，低于对照组的6.66%(P<0.05);观察组治疗效果满意度评分(90.02±2.15)分，高于对照组的(75.50±2.80)分(P<0.05);治疗总有效率86.67%，优于对照组的73.33%(P<0.05)。结论 宫颈癌治疗中于术前进行新辅助化疗，可以提高患者治疗效果、安全性、缩短手术时间，整体预后效果显著。
关键词：新辅助化疗;手术治疗;宫颈癌;术后并发症
中图分类号：R737.33 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.15.034
文章編号：1006-1959(2019)15-0106-03
Abstract：Objective To evaluate the effect of neoadjuvant chemotherapy in the treatment of cervical cancer and provide reference for the development of cervical cancer treatment.Methods 60 patients with cervical cancer admitted to our hospital from August 2016 to March 2018 were selected. They were divided into control group and observation group by random number table method， 30 cases each. The control group received routine surgery and the observation group received neoadjuvant chemotherapy before surgery. The intraoperative blood loss， operation time， treatment effect， postoperative complications， and patient satisfaction satisfaction scores of the two groups of cervical cancer patients were compared.Results The operation time of cervical cancer patients was (144.50±23.50) min， which was shorter than that of the control group (224.50±28.50) min (P<0.05). The total incidence of postoperative complications was 16.67%， which was lower than that of the control group 6.66% (P<0.05). The satisfaction score of the treatment group (90.02±2.15) was higher than that of the control group (75.50±2.80)(P<0.05); the total effective rate of treatment was 86.67%， which was better than 73.33% of the control group (P<0.05).Conclusion Neoadjuvant chemotherapy in the treatment of cervical cancer can improve the treatment effect， safety and shorten the operation time. The overall prognosis is significant.
Key words：Neoadjuvant chemotherapy;Surgical treatment;Cervical cancer;Postoperative complications
宫颈癌(cervical cancer)是女性常见性恶性肿瘤类型，发病率仅次于乳腺癌、直肠癌，是导致女性死亡的主要恶性肿瘤之一。近年来，医疗技术的发展，宫颈癌筛查工作的推广，成功降低了宫颈癌的发病率、死亡率，但是仍不可避免此疾病的发生，尤其是偏远地区、经济不发达地区，仍是影响患者生存、生活质量的主要疾病。宫颈癌集中多发于年龄30～55岁阶段人群，且发病有年轻化趋势。针对宫颈癌，患者临床症状、病情明显相关，宫颈上皮内瘤变、镜下早期浸润癌症状表现不明显，Ⅰb期开始阶段患者开始呈现阴道出血、排液等问题，癌组织破溃、继发感染情况下有脓血性液体伴恶臭情况，增加了宫颈癌患者的身心压力，甚至影响患者治疗的依从性和配合度效果，早期患者多以手术治疗达到根除病灶的目的，若患者瘤体较大手术根治效果不佳，为了巩固患者手术效果、减少宫颈癌复发率，开始采取术前化疗[1]。新辅助化疗的目的是缩小患者肿瘤瘤体、杀死转移细胞，提高手术治疗效果。基于此，本研究就我院60例宫颈癌患者作为实验对象，总结新辅助化疗的治疗价值，现报道如下。, http://www.100md.com(李博 李春晓)
关键词：新辅助化疗;手术治疗;宫颈癌;术后并发症
中图分类号：R737.33 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.15.034
文章編号：1006-1959(2019)15-0106-03
Abstract：Objective To evaluate the effect of neoadjuvant chemotherapy in the treatment of cervical cancer and provide reference for the development of cervical cancer treatment.Methods 60 patients with cervical cancer admitted to our hospital from August 2016 to March 2018 were selected. They were divided into control group and observation group by random number table method， 30 cases each. The control group received routine surgery and the observation group received neoadjuvant chemotherapy before surgery. The intraoperative blood loss， operation time， treatment effect， postoperative complications， and patient satisfaction satisfaction scores of the two groups of cervical cancer patients were compared.Results The operation time of cervical cancer patients was (144.50±23.50) min， which was shorter than that of the control group (224.50±28.50) min (P<0.05). The total incidence of postoperative complications was 16.67%， which was lower than that of the control group 6.66% (P<0.05). The satisfaction score of the treatment group (90.02±2.15) was higher than that of the control group (75.50±2.80)(P<0.05); the total effective rate of treatment was 86.67%， which was better than 73.33% of the control group (P<0.05).Conclusion Neoadjuvant chemotherapy in the treatment of cervical cancer can improve the treatment effect， safety and shorten the operation time. The overall prognosis is significant.
Key words：Neoadjuvant chemotherapy;Surgical treatment;Cervical cancer;Postoperative complications
宫颈癌(cervical cancer)是女性常见性恶性肿瘤类型，发病率仅次于乳腺癌、直肠癌，是导致女性死亡的主要恶性肿瘤之一。近年来，医疗技术的发展，宫颈癌筛查工作的推广，成功降低了宫颈癌的发病率、死亡率，但是仍不可避免此疾病的发生，尤其是偏远地区、经济不发达地区，仍是影响患者生存、生活质量的主要疾病。宫颈癌集中多发于年龄30～55岁阶段人群，且发病有年轻化趋势。针对宫颈癌，患者临床症状、病情明显相关，宫颈上皮内瘤变、镜下早期浸润癌症状表现不明显，Ⅰb期开始阶段患者开始呈现阴道出血、排液等问题，癌组织破溃、继发感染情况下有脓血性液体伴恶臭情况，增加了宫颈癌患者的身心压力，甚至影响患者治疗的依从性和配合度效果，早期患者多以手术治疗达到根除病灶的目的，若患者瘤体较大手术根治效果不佳，为了巩固患者手术效果、减少宫颈癌复发率，开始采取术前化疗[1]。新辅助化疗的目的是缩小患者肿瘤瘤体、杀死转移细胞，提高手术治疗效果。基于此，本研究就我院60例宫颈癌患者作为实验对象，总结新辅助化疗的治疗价值，现报道如下。, http://www.100md.com(李博 李春晓)